International Journal of Applied Research 2025; 11(10): 15-25

ISSN Print: 2394-7500
ISSN Online: 2394-5869
Impact Factor (RJIF): 8.69
IJAR 2025; 11(10): 15-25
www.allresearchjournal.com
Received: 10-07-2025
Accepted: 12-08-2025

Shaik Afrin
Bachelor of Pharmacy Student, Rathnam Institute of Pharmacy, Pidathapolur, Nellore, Andhra Pradesh, India

Kongi Kavyasudha
[1] Associate Professor, Department of Pharmacology, Rathnam Institute of Pharmacy, Pidathapolur, Nellore, Andhra Pradesh, India
[2] M.Pharm. Department of Pharmacology, Sree Venkateshwara University, Tirupati, Andhra Pradesh, India

Dr. Yadala Prapurna Chandra
Principal, Rathnam Institute of Pharmacy, Pidathapolur, Nellore, Andhra Pradesh, India

Corresponding Author:
Kongi Kavyasudha
[1] Associate Professor, Department of Pharmacology, Rathnam Institute of Pharmacy, Pidathapolur, Nellore, Andhra Pradesh, India
[2] M.Pharm. Department of Pharmacology, Sree Venkateshwara University, Tirupati, Andhra Pradesh, India

Pharmacological management of chemotherapy of breast cancer - includes side effects

Shaik Afrin, Kongi Kavyasudha, and Yadala Prapurna Chandra

DOI: https://www.doi.org/10.22271/allresearch.2025.v11.i10a.12911

Abstract
Breast cancer remains the most common malignancy among women worldwide and heavily relies on chemotherapy across all disease stages, including early, locally advanced, and metastatic settings. Significant advancements in chemotherapy have improved survival rates; however, treatment-associated toxicities such as myelosuppression, nausea, vomiting, mucositis, peripheral neuropathy, and cardiotoxicity continue to pose significant challenges. These adverse effects significantly impact patient quality of life, treatment adherence, and all things considered, therapeutic success. Effective pharmacological management involving antiemetics, hematopoietic growth factors, neuroprotective agents, and cardioprotective drugs is essential to mitigate these toxicities and ensure uninterrupted treatment. Chemotherapy regimens that include anthracyclines, taxanes, platinum compounds, and novel targeted therapies require personalized dosing strategies based on individual pharmacokinetics and pharmacodynamics to optimize efficacy while minimizing harm. Moreover, precision medicine techniques, including genomic profiling and biomarker-guided therapies a,s well as emerging drugs and advanced drug delivery systems, show promise in reducing adverse events and overcoming drug resistance mechanisms. Ongoing research, multidisciplinary collaboration, and timely updates to clinical guidelines are critical to refining supportive care, enhancing patient quality of life, reducing toxicity, and improving treatment outcomes. This comprehensive review integrates current chemotherapy protocols, associated toxicities, molecular mechanisms of resistance, and evidence-based pharmacological management strategies. These are vital for providing optimal, holistic, and personalized breast cancer care worldwide.

Keywords: Breast cancer chemotherapy, chemotherapy drugs, pharmacological management, Side effects

1. Introduction
Breast cancer remains the most prevalent malignancy among women worldwide, demanding complex multidisciplinary interventions for optimal patient outcomes. Chemotherapy is a cornerstone of breast cancer treatment and serves across stages, from early adjuvant to advanced metastatic disease. Over the decades, significant advances have refined chemotherapeutic regimens, improving survival rates and reducing recurrence [1]. However, chemotherapy is associated with a diverse and challenging spectrum of adverse effects, profoundly impacting quality of life and often limiting the intensity or duration of therapy. The pharmacological management of breast cancer chemotherapy side effects is, therefore, a critical aspect of oncological care [2]. Chemotherapeutic agents such as anthracyclines, taxanes, and platinum compounds cause notable toxicities like nausea, myelosuppression, mucositis, neuropathy, and cardiotoxicity, each requiring specific supportive interventions and monitoring [1, 2]. Targeted therapies and combination approaches further complicate this spectrum, necessitating tailored prophylaxis and management protocols [3]. The adverse effects, both acute and chronic, not only hamper patient well-being but can also compromise adherence and therapeutic efficacy [2, 4]. Understanding, anticipating, and mitigating these toxicities are essential responsibilities for clinicians.
Recent literature emphasizes evolving strategies for minimizing chemotherapy-induced complications. Novel antiemetic regimens, growth factors to address neutropenia, cardioprotective agents, and neuroprotective protocols are frequently incorporated into care pathways [1, 3, 5]. Mechanism-based drug selection, personalized dosing, and timely supportive care have shown tangible benefits in reducing toxicity-related hospitalizations and

improving treatment adherence [4, 5]. Moreover, systematic reviews of adjuvant and neoadjuvant therapies highlight the importance of balancing efficacy with manageable toxicity profiles, underscoring the ongoing need for therapeutic innovation [6]. In summary, effective pharmacological management of breast cancer chemotherapy side effects ensures treatment success and enhances patient quality of life. Continued research and updated clinical guidelines remain vital to address this rapidly evolving field, supporting each clinician and patient in our shared goal of improving cancer care [2, 4, 6].

2. Epidemiology and Pathophysiology

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related deaths among women worldwide. Its epidemiology reveals significant variation across geographic regions, influenced by genetic, environmental, and lifestyle factors [7, 8]. Globally, breast cancer incidence has been rising steadily, attributed to increased life expectancy, urbanization, and adoption of westernized lifestyles, including dietary changes, physical inactivity, and reproductive behaviors such as delayed childbirth and reduced breastfeeding [9, 10]. The World Health Organization underscores breast cancer as a significant public health concern, accounting for approximately 2.3 million new cases and 685,000 deaths globally in 2025 [11, 12].



Graph 1: Age at Diagnosis of Female Cases

Pathophysiologically, breast cancer is a heterogeneous disease characterized by multiple molecular subtypes, each with distinct genetic alterations and clinical behaviors. Key pathways involved in its development include hormone receptor signaling, HER2 amplification, and dysregulation of cell cycle control [13]. Genetic mutations in BRCA1, BRCA2, and other susceptibility genes significantly increase breast cancer risk, highlighting the complex interplay between inherited and acquired genetic factors. Molecular mechanisms such as DNA repair defects, epigenetic modifications, and aberrant receptor signaling contribute to tumor initiation, progression, and resistance to therapy. Breast cancer's diverse clinical manifestations and responsiveness to treatment have further highlighted the disease's molecular heterogeneity. Advances in multi-omic technologies have further illuminated the mechanisms regulating tumor biology, enabling more precise classification and the development of targeted therapies [13]. A comprehensive understanding of epidemiological patterns and underlying pathophysiology is essential to improving risk assessment, early detection, and personalized treatment strategies for breast cancer patients [14].



Fig 1: Pathophysiology of Breast Cancer

3. Role of Chemotherapy in Breast Cancer Treatment

One effective treatment option for bone cancer is chemotherapy, which uses cytotoxic medications to kill rapidly proliferating cancer cells across the body. It is administered before surgery as neoadjuvant therapy to shrink tumors and improve the feasibility of breast-conserving surgery or after surgery as adjuvant therapy to eliminate residual microscopic disease, thereby reducing the risk of recurrence and improving overall survival [15]. Neoadjuvant chemotherapy is particularly beneficial in aggressive breast cancer subtypes, including triple-negative and HER2-positive tumors, where rapid tumor reduction is critical [16]. For early-stage breast cancer, chemotherapy regimens often combine multiple agents such as anthracyclines, taxanes, and alkylating agents to maximize treatment effectiveness while tailoring regimens according to tumor biology and patient preference [17, 18]. Treatment planning also increasingly employs biomarkers and genomic profiling to identify patients most likely to benefit from chemotherapy, improving personalized therapeutic decision-making [18].

In metastatic breast cancer, chemotherapy primarily aims to control disease progression, relieve symptoms, and prolong survival, with treatment decisions personalized based on prior therapy, tumor subtype, and patient health status [19, 20]. Chemotherapy often gets mixed in combination with other systemic therapies, including targeted agents and hormone therapies, enhancing efficacy and expanding treatment options for difficult-to-treat subtypes [21]. Ongoing clinical trials and evolving guidelines continue to refine chemotherapy indications, dosing, and combinations, improving outcomes across breast cancer stages. Integration of new drugs and strategies promises to further augment the role of chemotherapy in comprehensive breast cancer care, balancing maximal effectiveness with patient-centered approaches.

4. Classification of Chemotherapeutic Agents

Table 1: Classification of Chemotherapeutic Agents

Class of Chemotherapeutic Agents	Examples	Mechanism of Action	Common Toxicities	Therapeutic Uses
Alkylating Agents [22]	Cyclophosphamide, Isosfamide, Melphalan, Cisplatin	Form covalent bonds with DNA causing cross-linking and strand breaks, inhibiting replication and transcription	Bone marrow suppression, nausea, hemorrhagic cystitis, nephrotoxicity	Used in early-stage adjuvant therapy, metastatic breast cancer, and combination regimens
Antimetabolites [23]	Methotrexate,5-Fluorouracil, Gemcitabine,Capecitabine	Inhibit DNA and RNA synthesis by mimicking natural	Myelosuppression, mucositis, diarrhea	Effective in early-stage and metastatic breast cancer,

		metabolites		often combined with other agents
Anthracyclines [24]	Doxorubicin, Epirubicin, Daunorubicin	Intercalate DNA, inhibit topoisomerase II, generate free radicals causing DNA damage	Cardiotoxicity, myelosuppression, alopecia	Backbone of neoadjuvant and adjuvant chemotherapy, also used in metastatic cases
Taxanes [25]	Paclitaxel, Docetaxel, Nab-paclitaxel	Stabilize microtubules, prevent cell division (mitosis)	Peripheral neuropathy, myelosuppression, hypersensitivity reactions	Neoadjuvant and adjuvant therapy, effective in metastatic breast cancer
Platinum Compounds [26]	Carboplatin, Cisplatin	Cross-link DNA leading to apoptosis	Nephrotoxicity, ototoxicity, neuropathy	Especially used in triple-negative breast cancer and metastatic disease
Topoisomerase Inhibitors [27]	Etoposide, Irinotecan	Inhibit topoisomerase enzymes, lead to DNA strand breaks	Myelosuppression, diarrhea, alopecia	Reserved for select metastatic breast cancer cases
Hormonal Therapies [28]	Tamoxifen, Aromatase inhibitors (Anastrozole, Letrozole)	Block estrogen receptor or inhibit estrogen synthesis	Hot flashes, thromboembolism, bone density loss	Treatment of hormone receptor-positive breast cancer
Targeted Therapies [27, 28]	Trastuzumab, Pertuzumab, Lapatinib	Monoclonal antibodies targeting HER2 receptor	Cardiotoxicity, infusion reactions	Approved for HER2-positive breast cancer therapy

5. Pharmacodynamics and Pharmacokinetics of Major Chemotherapeutic Agents

Pharmacodynamics and pharmacokinetics are critical in the efficacy and safety of significant chemotherapeutic agents used in breast cancer treatment [29]. Agents such as paclitaxel and epirubicin exhibit complex interactions affecting their disposition and therapeutic effects. Paclitaxel is administered via intravenous infusion and exhibits nonlinear pharmacokinetics, with dose-dependent increases in plasma concentrations and area under the curve (AUC), indicating saturation kinetics. Its half-life and clearance rates vary with dose, influencing exposure and toxicity profiles [30]. Epirubicin undergoes extensive hepatic metabolism to epirubicinol, with pharmacokinetics minimally altered by combination with paclitaxel, though the metabolite levels increase significantly [31]. The co-administration of paclitaxel and Cremophor EL inhibits epirubicin metabolism through competition for drug transport proteins like P-glycoprotein, leading to altered clearance and increased exposure [32, 33]. Pharmacodynamic modeling exposes a strong relationship between paclitaxel plasma concentration above threshold levels and the incidence of neutropenia, a vital dose-limiting toxicity [34]. The interaction between paclitaxel and epirubicin enhances myelosuppression, necessitating careful dosing schedules to minimize adverse effects without compromising therapeutic efficacy [33, 34].

These pharmacokinetic and pharmacodynamic characteristics inform clinical regimen design, including sequencing and dosing intervals, optimizing therapeutic outcomes in breast cancer chemotherapy while managing toxicity risks effectively [34].

6. Standard Chemotherapy Regimens and Protocols

Standard chemotherapy regimens play a pivotal role in breast cancer treatment, combining various cytotoxic agents tailored to tumor characteristics and patient-specific factors [35]. Regular protocols typically involve anthracyclines, taxanes, alkylating agents, and antimetabolites administered in two ways: sequentially or concurrently to maximize efficacy while balancing toxicity [36]. Postoperative adjuvant chemotherapy targets bitsy complaint that remains after surgery in trouble to lower the chance of urgency, specifically in cases with high- threat early- stage bone cancer [37]. Neoadjuvant chemotherapy is increasingly utilized before surgery to shrink tumors, improve surgical options, and assess treatment response, especially in aggressive subtypes such as triple-negative and HER2-positive cancers [38].

Widely adopted regimens include AC (doxorubicin and cyclophosphamide), followed by taxanes (paclitaxel or docetaxel) and TCH (taxane, carboplatin, trastuzumab), often tailored for HER2-positive disease [39]. Sequential single-agent chemotherapy is employed to maintain quality of life in patients with metastatic breast cancer, saving combination chemotherapy drugs for those whose disease is developing quickly [40]. Personalized approaches employing genomic assays and biomarkers guide regimen selection and duration decisions, optimizing treatment benefit [41]. Managing regimen-specific toxicities through supportive care remains essential. Continuous clinical trials and systematic reviews continue to refine chemotherapy protocols, improving survival and reducing adverse effects [42]. These evolving standards underline chemotherapy's integral role in comprehensive breast cancer care.

7. Mechanism of Drug Resistance in Breast Cancer

Drug resistance in breast cancer presents a significant barrier to effective treatment and long-term survival [43]. Multiple factors contribute to resistance, including genetic mutations, epigenetic modifications, and dynamic tumor microenvironment interactions [44]. A crucial mechanism involves overexpression of ATP-binding cassette (ABC) transporters, particularly P-glycoprotein and breast cancer resistance protein, which expel chemotherapeutic drugs, reducing intracellular drug concentrations and efficacy [45]. Additionally, alterations in key signaling pathways such as PI3K/Akt/mTOR and RAS/MAPK promote cancer cell survival despite therapeutic agents [46]. Epithelial-mesenchymal transition (EMT) facilitates drug resistance by conferring stem-like features and enhanced motility to cancer cells, correlating with metastasis and relapse [47]. Cancer stem cells contribute through their inherent ability to evade cytotoxic damage and regenerate heterogeneous tumor populations [48]. Moreover, hormone receptor-positive breast cancers develop resistance via mutations in estrogen receptor genes or loss of receptor expression, impairing endocrine therapies [49]. The extracellular matrix, immune cells, and stromal fibroblasts that make up the tumor microenvironment form protective niches that prevent drug penetration and encourage survival signals. Response to drugs, Epigenetic systems of regulation, and microRNAs have enormously altered it [48, 49]. Understanding these interconnected mechanisms is crucial for designing novel strategies to overcome resistance, enhancing treatment efficacy, and improving patient outcomes [50].



Fig 2: Mechanism of Drug Resistance in Breast Cancer

8. Adverse Effects of Chemotherapeutic Agents

8.1. Hematological Toxicity: Myelosuppression is the primary root cause of hematological toxicity, a frequent, hazardous side effect that results in thrombocytopenia, anemia, and neutropenia. This bone marrow suppression raises the risk of infection, results in fatigue and bleeding tendencies, and frequently results in changes or delays to chemotherapy dosages. Platinum compounds, taxanes, and anthracyclines often contribute to these effects [51].

8.2. Gastrointestinal Toxicity

Chemotherapy damages rapidly dividing gastrointestinal mucosal cells, resulting in nausea, vomiting, mucositis, and diarrhea. These toxicities impair nutritional intake and hydration, complicating cancer management. Antiemetics and supportive care have improved symptom control, but gastrointestinal toxicity remains a significant patient burden [52].

8.3. Cardiotoxicity

Anthracyclines and HER2-targeted agents are well-known for causing cardiotoxic effects ranging from arrhythmias to irreversible congestive heart failure. Routine cardiac monitoring before and during treatment is essential to detect early dysfunction and modify therapy accordingly [53].

8.4. Neurotoxicity:

Peripheral neuropathy, common with taxanes and platinums, manifests as numbness, tingling, and pain, predominantly in extremities. This dose-limiting toxicity may persist long term, affecting patients' quality of life [54].

8.5. Other Toxicities

Other notable adverse effects include alopecia, fatigue, skin changes, and cognitive impairments (chemo brain). Premature ovarian failure and infertility are significant concerns, especially in younger women undergoing chemotherapy [55].

Effective management through supportive care, dose adjustments, and ongoing research is critical for improving patient adherence and outcomes [56].



Fig 3: Adverse Effects of Chemotherapeutic Agents

9. Pharmacological Management of Chemotherapy Induced Side Effects

Chemotherapy-induced side effects significantly impair patient quality of life and treatment adherence [57]. Pharmacological management targets these toxicities comprehensively. For chemotherapy-induced nausea and vomiting (CINV), antiemetics such as serotonin receptor antagonists (ondansetron, palonosetron), neurokinin-1 receptor antagonists (aprepitant), corticosteroids, and benzodiazepines are mainstays of therapy [58, 59]. Granulocyte colony-stimulating factor (G-CSF) is one of the growth factors used to treat myelosuppression and neutropenia to lower the risk of infection. Chemotherapy-induced peripheral neuropathy is diagnosed with agents including gabapentin, pregabalin, and tricyclic antidepressants, albeit with limited efficacy [60]. For mucositis, mouthwashes containing antiseptics, anesthetics, and keratinocyte growth factor (palifermin) are Useful to mitigate symptoms. Diarrhea and constipation are managed with antidiarrheals (loperamide) or laxatives, respectively. Supportive medications, dose adjustments, and multidisciplinary care are essential for optimal management [61, 62]. Early intervention and tailored treatments based on patient risk factors improve outcomes and reduce chemotherapy interruptions, enhancing overall treatment success [63].



Fig 4: Pharmacological Management Chemotherapy Induced Side Effects

10. Recent Advances in Emerging Therapies

Recent advances in breast cancer therapy focus on improving survival and quality of life through precision medicine and innovative drug classes [64, 65]. Antibody-drug conjugates like trastuzumab deruxtecan combined with pertuzumab have set new standards for HER2-positive metastatic breast cancer, significantly extending progression-free survival [66, 67]. Oral Selective Estrogen Receptor Degraders (SERDs) such as camizestrant and imlunestrant offer promising options for hormone receptor-positive disease by overcoming resistance mechanisms, especially when combined with CDK4/6 inhibitors [68]. Immunotherapeutic approaches, including bispecific antibodies targeting PD-L1 and VEGF-A and oncolytic viruses, are advancing to boost anti-tumor immunity [69, 70]. By precisely targeting the mutant PIK3CA and estrogen receptor signaling pathways, accordingly, emerging small medicines like RLY-2608 and OP-1250 reduce adverse effects [71]. These therapies highlight a shift towards tailored treatments based on genomic profiling, poised to delay resistance and improve patient outcomes worldwide [72].

11. Future Perspectives

Future progress in breast cancer relies on bridging gaps in drug resistance, early detection, and personalized therapy [73]. Crucial challenges include understanding tumor heterogeneity, refining risk prediction models, and developing validated biomarkers for chemosensitivity and radiosensitivity [74]. Additionally, improved strategies for targeting dormant cells, integrating multi-omics, and ensuring equitable global access to innovations are needed [75]. Closing these research gaps will enable the next generation of precision therapies and better patient outcomes [76, 77].

12. Conclusion

Breast cancer treatment has seen remarkable advances in diagnosis, targeted therapies, and survivorship care, substantially improving outcomes and survival rates [80]. However, significant gaps remain, including limited effectiveness in resistant and metastatic disease, disparities in access to care, and an incomplete understanding of tumor heterogeneity [81]. Emerging technologies such as advanced imaging, multi-omic profiling, and artificial intelligence hold promise but require validation and equitable implementation [82]. Enhancing personalized medicine through biomarker discovery and improving integration of novel therapies like immunotherapy and antibody-drug conjugates are crucial [83]. Addressing these gaps by fostering collaborative research, optimizing clinical trial designs, and expanding global healthcare access will transform future breast cancer management, aiming for curative outcomes and improved quality of life worldwide [84, 85].

References

1. Valiyaveettil D, Joseph D, Malik M. Cardiotoxicity in breast cancer treatment: Causes and mitigation. Cancer Treat Res Commun. 2023;37:100760. doi:10.1016/j.ctarc.2023.100760
2. Wang X, Yang J, Zhang J, Yang H. Polypharmacy driven synergistic toxicities in elderly breast cancer chemotherapy drug management and adverse drug reactions: A mini review. Front Pharmacol. 2025;16:1654353. doi:10.3389/fphar.2025.1654353
3. Gumusay O, Callan J, Rugo HS. Immunotherapy toxicity: Identification and management. Breast Cancer Res Treat. 2022;192(1):1-17. doi:10.1007/s10549-021-06480-5
4. Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4/6 inhibitors: Basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review. Ther Adv Med Oncol. 2023;15:17588359231205848. doi:10.1177/17588359231205848
5. Amani O, Mazaheri MA, Moghani MM, Zarani F, Choolabi RH. Chemotherapy-induced cognitive impairment in breast cancer survivors: A systematic review of studies from 2000 to 2021. Cancer Rep. 2024;7(2):e1989. doi:10.1002/cnr2.1989
6. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325-48. doi:10.1200/JCO.20.01399
7. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer epidemiology, risk factors, classification, prognostic markers, and current treatment strategies An updated review. Cancers. 2021;13(17):4287. doi:10.3390/cancers13174287
8. Xu H, Xu B. Breast cancer: Epidemiology, risk factors and screening. Chin J Cancer Res. 2023;35(6):565-83. doi:10.21147/j.issn.1000-9604.2023.06.02
9. Roheel A, Khan A, Anwar F, Akbar Z, Akhtar MF, Imran Khan M, Sohail MF, Ahmad R. Global epidemiology of breast cancer based on risk factors: A systematic review. Front Oncol. 2023;13:1240098. doi:10.3389/fonc.2023.1240098
10. Xiong X, Zheng L-W, Ding Y, Chen Y-F, Cai Y-W, Wang L-P, Huang L, Liu C-C, Shao Z-M, Yu K-D. Breast cancer: Pathogenesis and treatments. Signal Transduct Target Ther. 2025;10(1):49. doi:10.1038/s41392-024-02108-4
11. Yara D, Oroszi T. Understanding breast cancer: A comprehensive review of epidemiology, risk factors, and treatment strategies. Adv Breast Cancer Res. 2025;14(01):1-15. doi:10.4236/abcr.2025.141001
12. Hackney L. Aetiology and epidemiology of breast cancer. In: Mercer C, Hogg P, Kelly J, editors. Digital Mammography. Cham: Springer; 2022. p. 51-69. doi:10.1007/978-3-031-10898-3_6
13. Smolarz B, Nowak AZ, Romanowicz H. Breast cancer epidemiology, classification, pathogenesis and treatment (Review of literature). Cancers. 2022;14(10):2569. doi:10.3390/cancers14102569
14. Soni L. Breast cancer: Types, symptoms, management. We Care. 2023. Available from: https://wecaregolp.com/breast-cancer/
15. Ochoa S, Hernández-Lemus E. Molecular mechanisms of multi-omic regulation in breast cancer. Front Oncol. 2023;13:1148861. doi:10.3389/fonc.2023.1148861
16. Claessens AKM, Ibragimova KIE, Geurts SME, Bos MEMM, Erdkamp FLG, Tjan-Heijnen VCG. The role of chemotherapy in treatment of advanced breast cancer: An overview for clinical practice. Crit Rev Oncol Hematol. 2020;153:102988. doi:10.1016/j.critrevonc.2020.102988
17. Tayebi A, TizMaghz A, Gorjizad M, Tavasol A, Tajaddini A, Rashnoo F, Vakili K, Behmanesh M, Olamaeian F, Ashoori M. Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes in breast cancer patients: A systematic review study. J Chemother. 2025;1-14. doi:10.1080/1120009X.2025.2468044
18. Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, Chopra R, Danso MA, Gomez HL, Homian NM, Kandil A, Kithaka B, Koczwara B, Moy B, Nakigudde G, Petracci FE, Rugo HS, El Saghir NS, Arun BK. Systemic treatment of patients with metastatic breast cancer: ASCO resource-stratified guideline. JCO Glob Oncol. 2024;10:e2300285. doi:10.1200/GO.23.00285
19. Du XL, Zhang Y, Parikh RC, Lairson DR, Cai Y. Comparative effectiveness of chemotherapy regimens in prolonging survival for two large population-based cohorts of elderly adults with breast and colon cancer in 1992-2009. J Am Geriatr Soc. 2015;63(8):1570-82. doi:10.1111/jgs.13523
20. Di Nardo P, Lisanti C, Garutti M, Buriolla S, Alberti M, Mazzeo R, Puglisi F. Chemotherapy in patients with early breast cancer: Clinical overview and management of long-term side effects. Expert Opin Drug Saf. 2022;21(11):1341-55. doi:10.1080/14740338.2022.2151584
21. Pathak M, Deo SV, Dwivedi SN, Sreenivas V, Thakur B, Julka PK, Rath G. Role of neoadjuvant chemotherapy in breast cancer patients: Systematic review and meta-analysis. Indian J Med Paediatr Oncol. 2019;40(01):48-62. doi:10.4103/ijmpo.ijmpo_21_18
22. Langeh U, Kumar V, Ahuja P, Singh C, Singh A. An update on breast cancer chemotherapy-associated toxicity and their management approaches. Health Sci Rev. 2023;9:100119. doi:10.1016/j.hsr.2023.100119
23. Ostios-Garcia L, Pérez DM, Castelo B, Herradón NH, Zamora P, Feliu J, Espinosa E. Classification of anticancer drugs: An update with FDA- and EMA-approved drugs. Cancer Metastasis Rev. 2024;43(4):1561-71. doi:10.1007/s10555-024-10188-5
24. Abotaleb M, Kubatka P, Caprnda M, Varghese E, Zolakova B, Zubor P, Opatrilova R, Kruzliak P, Stefanicka P, Büsselberg D. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. Biomed Pharmacother. 2018;101:458-77. doi:10.1016/j.biopha.2018.02.108
25. Chaurasia M, Singh R, Sur S, Flora SJS. A review of FDA approved drugs and their formulations for the

treatment of breast cancer. Front Pharmacol. 2023;14:1184472. doi:10.3389/fphar.2023.1184472
26. Ai L, Yi N, Qiu C, Huang W, Zhang K, Hou Q, Jia L, Li H, Liu L. Revolutionizing breast cancer treatment: Harnessing the related mechanisms and drugs for regulated cell death (Review). Int J Oncol. 2024;64(5):46. doi:10.3892/ijo.2024.5634
27. Lainetti PDF, Leis-Filho AF, Laufer-Amorim R, Battazza A, Fonseca-Alves CE. Mechanisms of resistance to chemotherapy in breast cancer and possible targets in drug delivery systems. Pharmaceutics. 2020;12(12):1193. doi:10.3390/pharmaceutics12121193
28. Roskoski R Jr. Targeted and cytotoxic inhibitors used in the treatment of breast cancer. Pharmacol Res. 2024;210:107534. doi:10.1016/j.phrs.2024.107534
29. Tong CWS, Wu M, Cho WCS, To KKW. Recent advances in the treatment of breast cancer. Front Oncol. 2018;8:227. doi:10.3389/fonc.2018.00227
30. Garattini S. Pharmacokinetics in cancer chemotherapy. Eur J Cancer. 2007;43(2):271-82. doi:10.1016/j.ejca.2006.10.015
31. Danesi R, Innocenti F, Fogli S, Gennari A, Baldini E, Di Paolo A, Salvadori B, Bocci G, Conte PF, Del Tacca M. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. Br J Clin Pharmacol. 2002;53(5):508-18. doi:10.1046/j.1365-2125.2002.01579.x
32. Evans WE. Pharmacodynamics of cancer chemotherapy: Childhood ALL as a model. Int Congr Ser. 2001;1220:203-22. doi:10.1016/S0531-5131(01)00298-9
33. Nagar S. Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy. In: Raffa RB, Tallarida RJ, editors. Chemo Fog. Vol. 678. New York: Springer; 2010. p.124-32. doi:10.1007/978-1-4419-6306-2_16
34. Tian H, Ma D, Tan X, Yan W, Wu X, He C, Zhong L, Zhang Y, Yu B, Zhang Y, Qi X. Platinum and taxane based adjuvant and neoadjuvant chemotherapy in early triple-negative breast cancer: A narrative review. Front Pharmacol. 2021;12:770663. doi:10.3389/fphar.2021.770663
35. He H, Cao Y. Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: A case study of paclitaxel. J Pharmacokinet Pharmacodyn. 2017;44(5):491-501. doi:10.1007/s10928-017-9540-2
36. Wang J, Wu S-G. Breast cancer: An overview of current therapeutic strategies, challenge, and perspectives. Breast Cancer: Targets Ther. 2023;15:721-30. doi:10.2147/BCTT.S432526
37. Petrelli F, Tomasello G, Parati MC, Ghidini A, Ghidini M, Borgonovo K, Cabiddu M, Ghilardi M, Reduzzi R, Gambini D, Zaniboni A, Faustinelli G, Garrone O. Different chemotherapy regimens and pathologic complete response in triple-negative breast cancer: An updated network meta-analysis of phase 3 trials. Medicina. 2024;60(2):341. doi:10.3390/medicina60020341
38. Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: An overview. BMC Med. 2015;13(1):195. doi:10.1186/s12916-015-0439-8
39. Zhang X-H, Hao S, Gao B, Tian W-G, Jiang Y, Zhang S, Guo L-J, Luo D-L. A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer. Oncotarget. 2016;7(51):84533-43. doi:10.18632/oncotarget.13023
40. Qari AS, Mowais AH, Alharbi SM, Almuayrifi MJ, Al Asiri AA, Alwatid SA, Aljohani AA, Alanazi RM, Al Thoubaity F. Adjuvant and neoadjuvant therapy for breast cancer: A systematic review. Eur J Breast Health. 2024;156-66. doi:10.4274/ejbh.galenos.2024.2023-12-16
41. Jung SY, Rosenzweig M. Sequential metastatic breast cancer chemotherapy: Should the median be the message? Front Public Health. 2013;1:49. doi:10.3389/fpubh.2013.00049
42. Tian Q, Lu B, Ye J, Lu W, Xie X, Wang X. Early stage primary ovarian mucinous carcinoma: Outcome-based clinicopathological study in comparison with serous carcinoma. J Int Med Res. 2016;44(2):357-66. doi:10.1177/0300060515597930
43. Das S, Dey MK, Devireddy R, Gartia MR. Biomarkers in cancer detection, diagnosis, and prognosis. Sensors. 2023;24(1):37. doi:10.3390/s24010037
44. Wu G-Y, Xiao M-Z, Hao W-C, Yang Z-S, Liu X-R, Xu D-S, Peng Z-X, Zhang L-Y. Drug resistance in breast cancer: Mechanisms and strategies for management. Drug Resist Updates. 2025;83:101288. doi:10.1016/j.drup.2025.101288
45. Saha S, Mahapatra S, Khanra S, Mishra B, Swain B, Malhotra D, Saha S, Panda VK, Kumari K, Jena S, Thakur S, Singh PK, Kundu GC. Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: From molecular insights to translational perspectives. Cancer Drug Resist. 2025. doi:10.20517/cdr.2025.69
46. Ye S, Chen S, Yang X, Lei X. Drug resistance in breast cancer is based on the mechanism of exocrine non-coding RNA. Discover Oncol. 2024;15(1):138. doi:10.1007/s12672-024-00993-3
47. Verma A, Patel K, Kumar A. Targeting drug resistance in breast cancer: The potential of miRNA and nanotechnology-driven delivery systems. Nanoscale Adv. 2024;6(24):6079-95. doi:10.1039/D4NA00660G
48. Lainetti PDF, Leis-Filho AF, Laufer-Amorim R, Battazza A, Fonseca-Alves CE. Mechanisms of resistance to chemotherapy in breast cancer and possible targets in drug delivery systems. Pharmaceutics. 2020;12(12):1193. doi:10.3390/pharmaceutics12121193
49. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62(1):233-47. doi:10.1146/annurev-med-070909-182917
50. Verma A, Patel K, Kumar A. Targeting drug resistance in breast cancer: The potential of miRNA and nanotechnology-driven delivery systems. Nanoscale Adv. 2024;6(24):6079-95. doi:10.1039/D4NA00660G
51. Salemme V, Centonze G, Avalle L, Natalini D, Piccolantonio A, Arina P, Morellato A, Ala U, Taverna D, Turco E, Defilippi P. The role of tumor microenvironment in drug resistance: Emerging technologies to unravel breast cancer heterogeneity. Frontiers in Oncology. 2023;13:1170264.

52. Modi A, Roy D, Sharma S, Vishnoi JR, Pareek P, Elhence P, Sharma P, Purohit P. ABC transporters in breast cancer: Their roles in multidrug resistance and beyond. Journal of Drug Targeting. 2022;30(9):927-947.
53. Folorunso SA, Abiodun OO, Abdus-salam AA, Wuraola FO. Evaluation of side effects and compliance to chemotherapy in breast cancer patients at a Nigerian tertiary hospital. Ecancermedicalscience. 2023;17:1537.
54. Rashid N, Koh HA, Baca HC, Li Z, Malecha S, Abidoye O, Masaquel A. Clinical Impact of Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System. Journal of Managed Care & Specialty Pharmacy. 2015;21(10):863-871.
55. Anisha S, Nandha SR, Suseela SS. Adverse drug reactions monitoring among breast cancer patients in a tertiary care teaching hospital. International Journal of Basic & Clinical Pharmacology. 2023;12(3):358-361.
56. Ann P. The Effects of Chemotherapy on Your Body. Healthline. 2025. Available from: https://share.google/RRWumi66ZZ5BISvKA
57. Nguyen SM, Pham AT, Nguyen LM, Cai H, Tran TV, Shu XO, Tran HTT. Chemotherapy-Induced Toxicities and Their Associations with Clinical and Non-Clinical Factors among Breast Cancer Patients in Vietnam. Current Oncology. 2022;29(11):8269-8284.
58. Ambreen U, Ahsan M. Mitigating Chemotherapy Toxicities in Breast Cancer: The Potential of Arglabin Therapy. Asian Pacific Journal of Cancer Prevention. 2025;26(2):359-360.
59. Lewis L, Thompson B, Stellmaker R, Koelmeyer L. Body composition and chemotherapy toxicities in breast cancer: A systematic review of the literature. Journal of Cancer Survivorship. 2025;19(3):914-929.
60. Maroun JA, Anthony LB, Blais N, Burkes R, Dowden SD, Dranitsaris G, Samson B, Shah A, Thirlwell MP, Vincent MD, Wong R. Prevention and Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer: A Consensus Statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Current Oncology. 2007;14(1):13-20.
61. Wang C, Chen S, Jiang W. Treatment for chemotherapy-induced peripheral neuropathy: A systematic review of randomized control trials. Frontiers in Pharmacology. 2022;13:1080888.
62. Alyamany R, Alnughmush A, Alzahrani H, Alfayez M. Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia. Current Oncology. 2024;31(12):8094-8109.
63. Brianna, Lee SH. Chemotherapy: How to reduce its adverse effects while maintaining the potency? Medical Oncology. 2023;40(3):88.
64. Yan H, Wang P, Yang F, Cheng W, Chen C, Zhai B, Zhou Y. Anticancer therapy-induced adverse drug reactions in children and preventive and control measures. Frontiers in Pharmacology. 2024;15:1329220.
65. Shrmeka MS, Semman MF, Moges BT, Dereja FN, Garedo AW. Chemotherapy-related adverse drug reaction and associated factors among adult cancer patient attending Jimma medical center oncology unit, Southwest Ethiopia. PLOS One. 2025;20(5):e0321785.
66. Yeo W, Chan. Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. Breast Cancer: Targets and Therapy. 2011;151:151-158.
67. Colella G, Boschetti CE, Vitagliano R, Colella C, Jiao L, King-Smith N, Li C, Nuoh Lau Y, Lai Z, Mohammed AI, Cirillo N. Interventions for the Prevention of Oral Mucositis in Patients Receiving Cancer Treatment: Evidence from Randomised Controlled Trials. Current Oncology. 2023;30(1):967-980.
68. Liu Y. Recent advances and updated highlights in breast cancer pathologic diagnosis: A narrative review. Translational Breast Cancer Research. 2025;6:3-3.
69. Demircan NV, Bese N. New Approaches in Breast Cancer Radiotherapy. European Journal of Breast Health. 2024;20(1):1-7.
70. Jazieh K, Bell R, Agarwal N, Abraham J. Novel targeted therapies for metastatic breast cancer. Annals of Translational Medicine. 2020;8(14):907-907.
71. Ellis P. Recent advances in systemic therapy for breast cancer: New technologies for a new era. Breast Cancer Research. 2009;11(4):107:1-12.
72. Corti C, Koca B, Rahman T, Mittendorf E, Tolaney S. Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer. ImmunoTargets and Therapy. 2025;14:339-357.
73. Bai J, Gao Y, Zhang G. The treatment of breast cancer in the era of precision medicine. Cancer Biology & Medicine. 2025;1-26.
74. Kingston B, Johnston S. Novel Treatments in Breast Cancer. Clinical Medicine Insights: Therapeutics. 2016;8:CMT.S18492.
75. Hong R, Xu B. Breast cancer: An up-to-date review and future perspectives. Cancer Communications. 2022;42(10):913-936.
76. Venkataraman J, Mokbel K. Key breast cancer highlights from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Translational Breast Cancer Research. 2025;6:26-26.
77. Basingab F, Alshahrani O, Alansari I, Almarghalani N, Alshelali N, Alsaiary A, Alharbi N, Zaher K. From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment. Breast Cancer: Targets and Therapy. 2025;17:27-51.
78. Sun L, Jia X, Wang K, Li M. Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes. The Breast. 2024;78:103830.
79. Ditsch N, Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference. Breast Care. 2025;20(4):288-297.
80. Wagle NS, Nogueira L, Devasia TP, Mariotto AB, Yabroff KR, Islami F, Jemal A, Alteri R, Ganz PA, Siegel RL. Cancer treatment and survivorship statistics, 2025. CA: A Cancer Journal for Clinicians. 2025;75(4):308-340.
81. Khan AQ, Touseeq M, Rehman S, Tahir M, Ashfaq M, Jaffar E, Abbasi SF. Advances in breast cancer diagnosis: A comprehensive review of imaging,

biosensors, and emerging wearable technologies. Frontiers in Oncology. 2025;15:1587517.
82. Addissouky TA, El Sayed IET, Ali MMA, Alubiady MHS, Wang Y. Harnessing innovation for the future of breast cancer management. Clinical Research in Oncology. 2024;1(1):10-17.
83. De Sanctis R, Tiberio P, Zambelli A, Santoro A. Transforming Breast Cancer Care: Cutting-Edge Insights and Future Directions. Journal of Clinical Medicine. 2024;13(22):6697.
84. Kavyasudha K, *et al*. A review Cure the cancer with *amygdalin/laetrile*. Asian Journal of Medical and Pharmaceutical Sciences. 2017;5(2):1-5.
85. Suchitra M, *et al*. Stem cell therapy in progression of breast cancer: An overview. EC Pharmacology and Toxicology. 2025;13(3):1-12.